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A B S T R A C T
Increasing resistance of bacteria to antibiotics is a serious global challenge and there is a need to unlock the
potential of novel antibacterial targets. One such target is the essential prokaryotic endoribonuclease RNase E.
Using a combination of in silico high-throughput screening and in vitro validation we have identified three novel
small molecule inhibitors of RNase E that are active against RNase E from Escherichia coli, Francisella tularensis
and Acinetobacter baumannii. Two of the inhibitors are non-natural small molecules that could be suitable as lead
compounds for the development of broad-spectrum antibiotics targeting RNase E. The third small molecule
inhibitor is glucosamine-6-phosphate, a precursor of bacterial cell envelope peptidoglycans and lipopoly-
saccharides, hinting at a novel metabolite-mediated mechanism of regulation of RNase E.
1. Introduction
For the majority of bacterial infections, the only treatment(s)
available are antibiotics. However, many traditional antibiotics are now
ineffective due to the emergence of antimicrobial resistant strains and,
consequently, there is a growing need for the development of novel
antibacterial strategies. RNA degradation has recently been identified
as a cellular process that could potentially be targeted by antibiotics
[1,2]. This is because RNA degradation is both an essential component
of RNA metabolism and there are fundamental differences between
prokaryotic and human ribonucleases (RNases), the enzymes re-
sponsible for RNA turnover (reviewed in Refs. [1,2]). One RNase has
been specifically identified as a potential antibacterial target, the en-
doribonuclease RNase E [1].
RNase E is an attractive antibacterial target for several reasons.
Firstly, RNase E is an essential enzyme, meaning that RNase E inhibitors
would be expected to have antibacterial properties. Studies conducted
in the late 1970s demonstrated that inactivation of RNase E is lethal to
Escherichia coli [3,4]. Since then, considerable effort has been expended
in trying to understand the role(s) that RNase E plays. In E. coli, RNase E
is now known to be multi-functional, having critical roles in rRNA and
tRNA maturation and mRNA and rRNA decay (see Refs. [5,6] for recent
reviews of RNase E functions). It is possible that RNase E is indis-
pensable as a consequence of this broad functionality. However, more
recent studies are beginning to suggest that there may be very specific
functions of RNase E that are necessary under certain growth conditions
[7,8]. A second reason for selecting RNase E as an antibacterial target is
that RNase E has been reported to play direct roles in the virulence of
the pathogens Salmonella enterica [9] and Yersinia pestis [10]. Sup-
pression of virulence phenotypes generally does not kill bacteria, but it
does disarm them, and targeting virulence factors has been identified as
a valid platform for developing antibiotics [reviewed in 11]. Finally,
RNase E is a suitable antibacterial target because it is highly conserved
and widely distributed amongst Gram-negative bacteria but there is no
known orthologue in humans [12]. Therefore, it would be hoped that
specific RNase E inhibitors would be detrimental to bacterial survival
but non-toxic to humans.
RNase E endoribonucleolytically cleaves within single-stranded A/
U-rich regions of its RNA substrates and has a strong preference for
substrates with a 5′ monophosphate [13,14]. The N-terminal domain
(NTD) of RNase E is responsible for the endoribonuclease activity [15].
It is a homotetramer, organised as a dimer of dimers, with each
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monomeric unit consisting of five subdomains: an RNase H domain, an
S1 domain, a 5′ sensor domain, a deoxyribonuclease (DNase) I domain
and a small domain [16]. The active site is formed by the DNase I and
S1 subdomains [16]. It contains an essential catalytic magnesium ion,
coordinated by two aspartates from the DNase I subdomain (D303,
positioned by N305, and D346 in E. coli RNase E), that is required for
hydrolytic cleavage of an RNA substrate and an RNA-binding site, the
uracil pocket of the S1 subdomain (including key amino acids F57, F67
and K112), that determines the A/U-rich substrate specificity [16,17]
(Supplementary Fig. S1). The phosphorylation state of the substrate is
recognised by the 5′ sensor subdomain through interactions between a
5′ monophosphate and conserved arginine and threonine residues
(R169 and T170 in E. coli RNase E) which are positioned by a conserved
glycine and valine (G124 and V128 in E. coli RNase E) [16,18,19]
(Supplementary Fig. S1). We reasoned that any small molecule capable
of binding at, and therefore blocking, the active site and/or the 5′
sensor region would be a potential inhibitor of RNase E [20].
As a first step in realising the potential of RNase E as an anti-
bacterial target, a recent collaboration between our lab and the
McDowall group (University of Leeds, UK) used structure-based virtual
high-throughput screening (vHTS) against the active site and 5′ sensor
region of E. coli RNase E to identify the first small molecule inhibitors of
RNase E [20]. Unfortunately, the inhibitors identified in Kime et al.
[20] are no longer commercially available at a cost that would enable
us to explore their development as antimicrobials. Therefore, we
decided to search for inhibitors that are commercially available and,
ideally, are relatively inexpensive. In the current study we have now
identified and characterised a further three novel small molecule in-
hibitors of RNase E, all of which are commercially available and in-
expensive. Initially, structure-based vHTS was performed, using a
screening library of commercially available chemical building blocks, to
identify small molecules predicted to inhibit RNase E by binding to/
blocking the active site or 5′ sensor region. Candidate inhibitors were
then filtered by docking score, known physicochemical properties and
economic factors; resulting in the selection of eleven small molecules
that were screened in vitro for inhibitory activity against purified E. coli
RNase E NTD. The small molecules that inhibited E. coli RNase E NTD
were: AS2, a non-natural small molecule, predicted to target the active
site; AS4/glucosamine-6-phosphate (GlucN6P), a natural precursor of
bacterial cell envelope peptidoglycans and lipopolysaccharides, also
predicted to target the active site; and 5′S1, a non-natural small mo-
lecule, predicted to target the RNA-binding 5′ sensor region. Further-
more, each inhibitor also inhibited the RNase E NTD from bacterial
pathogens of importance to the health (Acinetobacter baumannii [21])
and defence (Francisella tularensis [22]) sectors. We anticipate that the
identified novel small molecule RNase E inhibitors will provide a
foundation for the development of broad-spectrum antibiotics targeting
RNase E. In addition, the finding that RNase E is inhibited by the me-
tabolite GlucN6P suggests that RNase E activity could be regulated via a
metabolite-mediated mechanism.
2. Materials and Methods
2.1. Structure-based virtual high-throughput screening (vHTS) for small
molecule inhibitors of RNase E
RNase E structure preparation – E. coli RNase E NTD crystal structures
(closed conformation: 2BX2, [16]; open conformation: 2VMK [18])
were opened in the program MOE (Molecular Operating Environment,
2013.08; Chemical Computing Group Inc., 1010 Sherbrooke St. West,
Suite #910, Montreal, QC, Canada, H3A 2R7). An apo-2BX2 structure
was generating by removing the co-crystallised bound RNA substrate
from 2BX2. MOE's QuickPrep function was used to subject apo-2BX2
and 2VMK to protonation and energy minimisation, using the Am-
ber12:EHT force field parameters [23,24].
Identification of putative small molecule-binding sites in RNase E – The
MOE Alpha Site Finder function was used to identify putative small
molecule-binding sites in the prepared E. coli RNase E NTD structures. A
putative small molecule-binding site at the active site of E. coli RNase E
was selected in the apo-2BX2 structure based on the presence of the
catalytic residues D303, N305 and D346 and a putative small molecule-
binding site at the 5′ sensor region was selected in the 2VMK structure
based on the presence of the key amino acids G124, V128, R169 and
T170. Each putative small molecule-binding site was defined by the
placement of dummy atoms.
Small molecule structure preparation – Structures of P6 (Maybridge:
HTS01081) and P11 (Maybridge: SEW06445) were retrieved from
Maybridge [25] and the structures for the Sigma Aldrich (Building
Blocks) screening library (67,449 compounds from a vendor catalogue
of 109,823 compounds) were retrieved from the ZINC database
[26,27]. All small molecule structures were prepared using the Quick-
Prep function in MOE as described above for the RNase E structures.
In silico molecular docking of small molecules into the active site of
RNase E – The MOE Dock function was used to dock the small molecules
from the Sigma Aldrich (Building Blocks) screening library into the
active site of the apo-2BX2 E. coli RNase E NTD structure using ‘Triangle
Matcher’ placement methodology and 30 placement poses. RNase E-
small molecule complexes were scored according to the London dG
scoring function (MOE) and subjected to a rigid receptor refinement
step with no second rescoring. The 10 lowest-energy unique RNase E-
small molecule complex conformations were retained for each small
molecule.
In silico molecular docking of small molecules into the 5′ sensor region of
RNase E – The MOE Dock function was used to dock RNase E inhibitors
P6 (Maybridge: HTS01081) and P11 (Maybridge: SEW06445) [20] into
the 5′ sensor region of the 2VMK E. coli RNase E NTD structure as de-
scribed above for docking small molecules into the active site. The re-
sults were combined to generate a pharmacophore query in MOE. This
was applied to the small molecules from the Sigma Aldrich (Building
Blocks) screening library. 500 small molecules with the lowest root-
mean-square deviation (RMSD) compared to the pharmacophore query
were redocked into the 5′ sensor of the 2VMK E. coli RNase E NTD
structure using the docking parameters described above for docking
small molecules into the active site.
Filtering of the vHTS results – The vHTS results against the active site
and the 5′ sensor region of E. coli RNase E were collated and were
ranked from best to worst based on docking score. Small molecules with
known undesirable physicochemical properties (nucleosides, nucleo-
tides and nucleoside/nucleotide analogues; metal chelators; insoluble
small molecules; unstable small molecules; toxic small molecules) were
removed. Finally, small molecules reported to have desirable bioac-
tivity were masked before removing small molecules that cost more
than £5 per mg.
2.2. Molecular docking of selected small molecules into E. coli RNase E NTD
Following vHTS, the Dock function in MOE was used to dock the
selected small molecules into the apo-2BX2 E. coli RNase E NTD
structure. Small molecules AS1-9 were docked into the active site and
small molecules 5′S1 and 5′S2 into the 5′ sensor region of apo-2BX2
using ‘Triangle Matcher’ placement methodology and 100 placement
poses. RNase E-small molecule complexes were scored according to the
London dG scoring function (MOE) and subjected to a rigid receptor
refinement step with no second rescoring. The 30 lowest-energy unique
RNase E-small molecule complex conformations were retained for each
small molecule.
2.3. Cloning, expression and purification of RNase E NTDs
Cloning, expression and purification of the NTDs from E. coli RNase
E (aa 1–529), F. tularensis RNase E (aa 1–543) and A. baumannii RNase E
(aa 1–544) has been described previously [28]. Briefly, each of the
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RNase E NTDs was expressed as an N-terminally His10-tagged protein
from the pET16b expression vector (Novagen). The expression vector
for E. coli RNase E NTD was kindly provided by Prof. Ben Luisi (Uni-
versity of Cambridge, UK). Codon-optimised genes for F. tularensis and
A. baumannii RNase E NTD were obtained from GeneArt (Life Tech-
nologies) and ligated between the NdeI and BamHI restriction sites of
pET16b. Each RNase E NTD was expressed in E. coli BL21(DE3)pLysS
transformed with the respective expression vector. Each expression
strain was grown to OD600 = 0.6 in 500 ml LB supplemented with
100 μg/ml ampicillin, at 37 °C, with shaking at 250 rpm. Isopropyl β-D-
1-thiogalactopyranoside (IPTG) was added to a final concentration of
1 mM to induce expression of the RNase E NTD. Cells were incubated
for a further 3 h, at 37 °C, with shaking at 250 rpm before being har-
vested by centrifugation at 7000 rcf and 4 °C for 20 min. The cell pellet
was stored frozen at -20 °C prior to RNase E NTD purification. Frozen
cell pellets were thawed on ice and resuspended in 50 ml Buffer A
(20 mM Tris-HCl (pH 8), 500 mM NaCl, 20 mM imidazole) supple-
mented with a cOmpleteTM ethylenediaminetetraacetic acid (EDTA)-
free protease inhibitor cocktail tablet (Roche). Cells were lysed by so-
nication (Sonics Vibra Cell VCX 500 sonicator): 3.3 s on, 9.9 s off for
10 min. Lysate was clarified by centrifugation at 40,000 g and 4 °C for
20 min and loaded onto a 5 ml HisTrap FF column (GE Healthcare)
equilibrated in Buffer A using an ÄKTA Purifier (GE Healthcare). Bound
proteins were eluted in a linear gradient to 100% Buffer B (20 mM Tris-
HCl (pH 8), 500 mM NaCl, 500 mM imidazole) applied over 30 ml.
Fractions containing RNase E NTD were pooled and loaded onto a Hi-
Prep 26/10 Desalting column (GE Healthcare) equilibrated in Buffer C
(20 mM Tris-HCl (pH 8), 500 mM NaCl, 10 mM MgCl2, 10 mM EDTA,
10 mM dithiothreitol (DTT) and 10% (v/v) glycerol) using an ÄKTA
Purifier. Fractions containing RNase E NTD were pooled, concentrated
by centrifugation using a Vivaspin 20 (MWCO 10 kDa) centrifugal
concentrator (Sartorius) and stored frozen at -80 °C.
2.4. In vitro screening of candidate small molecule inhibitors against E. coli
RNase E NTD (discontinuous RNase E assay)
Discontinuous RNase E assays were carried out essentially as de-
scribed previously [28]. Briefly, control reaction mixtures (30 μl) con-
tained: 5 nM purified E. coli RNase E NTD; 1 μM 5′ phosphorylated, 3′
fluorescein amidite (FAM)-labelled p-UUUACAGUAUUUG-FAM (5′-p-
RNA13-FAM-3′) RNA substrate (Dharmacon); 25 mM Tris-HCl (pH 8);
100 mM NaCl; 15 mMMgCl2; 1 mM DTT; 37.5 mg/ml Ficoll 70; and 5%
(v/v) dimethyl sulfoxide (DMSO). Screening reaction mixtures were
identical to the control except that they were supplemented with 0.625,
1.25, 2.5, 5 or 10 mM of the respective small molecule (Sigma), as
indicated. All reactions were incubated at 28 °C for 45 min and ter-
minated by the addition of 0.5 vol of quench buffer (95% (v/v) for-
mamide, 20 mM EDTA). The reaction products were resolved by de-
naturing 7.5 M urea 20% polyacrylamide gel electrophoresis (PAGE)
and gels were visualised using a G:Box UV transilluminator (Syngene).
2.5. Real-time FRET-based RNase E assay
Assays were carried out in black 96-well microplates (ThermoFisher
Scientific). Modified target-guide RNA substrate was prepared by an-
nealing a 5′ hydroxylated, 3′ FAM-labelled 18-mer (5′–OH–GGAUCGG
AGUUUUAAAUU-FAM-3′) target RNA (Dharmacon) and a 5′ phos-
phorylated, 3′ tetramethyl-6-carboxyrhodamine (TAMRA)-labelled 13-
mer (5′-p-UUUUCUCCGAUCC-TAMRA-3′) guide RNA (Dharmacon) at a
molar ratio of 1:1.14 at 28 °C for 15 min. Reaction mixtures (100 μl)
contained: 5 nM RNase E NTD; 0.1–2 μM modified target-guide RNA
substrate; 0–10 mM AS2, AS4 or 5′S1; 25 mM Tris-HCl (pH 8); 100 mM
NaCl; 15 mMMgCl2; 1 mM DTT; 37.5 mg/ml Ficoll 70; 5% (v/v) DMSO.
Reaction components were incubated at 28 °C for 15 min prior to in-
itiating the reaction by the addition of the modified target-guide RNA
substrate. Fluorescence intensity measurements were collected at 32-s
intervals for 2 h using a BioTek H1 Synergy plate reader with excitation
and emission wavelengths of 494 nm and 520 nm, respectively. Data
corresponding to up to 50% reaction completion were used to de-
termine the rate of RNA cleavage.
To determine the half maximal inhibitory concentration (IC50), data
were fitted to a three-parameter IC50 single-site inhibition model in
GraFit5 (Erithacus software):
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where y is the rate of RNA cleavage determined at inhibitor con-
centration x; Range is the difference between the theoretical maximal
and minimal rate of RNA cleavage; IC50 is the concentration of inhibitor
at half the Range; and s is the slope factor (a measure of how steeply the
linear portion of the sigmoid falls).
For kinetic analysis, data were fitted to the Michaelis-Menten
equation in GraFit5:
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where V0 is the measured rate of RNA cleavage, Vmax is the maximal
theoretical velocity, [S] is the concentration of RNA substrate and Km is
the apparent Michaelis constant.
3. Results
3.1. Structure-based vHTS for small molecule inhibitors of RNase E
In order to identify candidate RNase E inhibitors with the potential
to bind at the active site and/or 5′ sensor region of RNase E we decided
to use structure-based vHTS. As part of a collaborative project, we
previously identified the first small molecule inhibitors of RNase E
through structure-based vHTS of a Maybridge screening library against
the active site and 5′ sensor region of E. coli RNase E [20]. A potential
benefit of using a Maybridge screening library for vHTS is that it may
increase the chance of identified inhibitors being promising lead com-
pounds for drug development because the screening libraries have been
specifically designed to contain chemical building blocks (small mole-
cules that can be readily converted to secondary chemicals and inter-
mediates) with drug-like properties [25]. However, Maybridge use Li-
pinski's rule of five (≤ 5 hydrogen bond donors, ≤ 10 hydrogen bond
acceptors, molecular mass ≤ 500 Da and an octanol-water partition
coefficient (log P)≤ 5) [29] to assign drug-like properties. While these
rules have proved useful for predicting which small molecules can pe-
netrate human cells, they are less useful for predicting small molecule-
penetration of bacterial cells, a prerequisite for the majority of anti-
microbials [11]. Also, the commercial availability of the small mole-
cules included in the Maybridge screening libraries is variable. Un-
fortunately, the monetary cost of obtaining the “Maybridge” RNase E
inhibitors identified in Kime et al. [20], in the amounts required for
further analysis, was prohibitive. Therefore, we decided to conduct a
second vHTS, this time using a screening library of commercially
available small molecules. To this end, we selected the Sigma Aldrich
(Building Blocks) screening library that is available through the ZINC
database because it is composed of chemical building blocks (small
molecules with potential for chemical elaboration) that are commer-
cially available from Sigma Aldrich [26,27]. The Sigma Aldrich
(Building Blocks) screening library includes 67,449 small molecules
from a catalogue of 109,823 [26]. Although ZINC provide an option to
further filter the small molecules included in the screening library
based on their perceived drug-like properties, due to the questionable
relevance of applying Lipinski's rule of five to antimicrobials, we did
not do so.
The first round of structured-based vHTS focused on identifying
small molecules with the potential to bind at the active site of RNase E.
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A putative ligand-binding pocket at the active site of E. coli RNase E was
defined based on the presence of amino acids D303, N305 and D346
(see Materials and Methods for details). The complete Sigma Aldrich
(Building Blocks) screening library (67,449 compounds) was then
screened against this site. A second round of vHTS targeted the 5′ sensor
region. A potential ligand-binding site at the 5′ sensor region was de-
fined based on the presence of amino acids G124, V128, R169 and T170
(see Materials and Methods for details). Due to the higher incidence of
false positives for small molecules predicted to bind at the 5′ sensor
region (18/21) compared to the active site (6/9) during our previous
vHTS [20], we decided to prefilter the Sigma Aldrich (Building Blocks)
screening library using a pharmacophore query based on previously
reported RNase E inhibitors P6 and P11 [20] (see Materials and
Methods for details). A subset of 500 small molecules (those with the
lowest RMSD relative to the pharmacophore query) were subsequently
screened against the 5′ sensor region of E. coli RNase E.
The results from both rounds of vHTS were collated and the small
molecules were ordered from best to worst based on docking score. The
results were then filtered to remove small molecules with undesirable
physicochemical properties. This included the removal of nucleosides,
nucleotides and nucleoside/nucleotide analogues; metal chelators e.g.
EDTA; small molecules known to be insoluble; small molecules known
to be unstable; and small molecules known to be toxic. These results
were then masked to ensure the inclusion of small molecules with re-
ported desirable bioactivity before filtering the remaining results to
remove small molecules that were not commercially available at a
reasonable cost using an arbitrary monetary cutoff of £5 per mg.
Masking small molecules with desirable bioactivity ensured the inclu-
sion of heparin, which does not meet the monetary cutoff but has been
reported to have antimicrobial properties [30]. Using these criteria,
nine small molecules predicted to bind/block the active site (AS1-9)
and two small molecules predicted to bind/block the 5′ sensor region
(5′S1 and 5′S2) were selected for further analysis (see Supplementary
Table S1 for molecular details).
These small molecules were redocked into E. coli RNase E using a
similar process to the vHTS. However, a greater number of starting
placement poses were used (100 compared to 30) and a greater number
of unique RNase E-small molecule complex conformations were re-
tained (30 compared to 10) to increase the likelihood of finding the
lowest-energy RNase E-small molecule complex conformation. The
lowest-energy RNase E-small molecule complex for each of the poten-
tial small molecule inhibitors docked into the active site (small mole-
cules AS1-9) or the 5′ sensor region (small molecules 5′S1 and 5′S2) of
E. coli RNase E, together with the corresponding docking score, is
shown in Fig. 1.
3.2. In vitro screening of candidate small molecule inhibitors against E. coli
RNase E NTD
In order to determine whether the small molecules selected through
vHTS inhibit RNase E, AS1-9, 5′S1 and 5′S2 were screened for in-
hibitory activity against E. coli RNase E NTD using an in vitro dis-
continuous assay that has been described previously [28]. In this assay,
5′-p-RNA13-FAM-3′, a 13-mer model RNA substrate of RNase E [16,31],
is cleaved by E. coli RNase E NTD, at a single site, to generate an un-
labelled octamer and a 3′ FAM-labelled pentamer product. Inhibitory
activity of a small molecule manifests as an increase in the amount of
full-length 5′-p-RNA13-FAM-3′ RNA substrate and a decrease in the
amount of 3′ FAM-labelled pentamer product detectable at the end of
the assay relative to a control assay performed in the absence of small
molecule. The inhibitory activity of 0.625, 1.25, 2.5, 5 or 10 mM AS1-9,
5′S1 and 5′S2 was evaluated using this assay (Supplementary Fig. S2).
The data obtained in the absence of small molecule and in the presence
of 10 mM AS1-4, AS6-9 or 5′S1 are presented in Fig. 2A. At 10 mM, the
highest concentration tested, small molecules AS1, AS3 and AS7-9 did
not inhibit E. coli RNase E NTD. Small molecules AS5 and 5′S2
interfered with the PAGE assay, masking the band representing the 3′
FAM-labelled pentamer product (Supplementary Figs. S2E and K).
However, no full-length 5′-p-RNA13-FAM-3′ RNA substrate could be
detected at the end of the assay in the presence of either 10 mM AS5 or
10 mM 5′S2, indicating that they also do not inhibit E. coli RNase E
NTD. In contrast, 10 mM AS2, AS4 or 5′S1 appeared to almost com-
pletely inhibit E. coli RNase E NTD and a fourth small molecule, AS6,
partially inhibited E. coli RNase E NTD. Since AS6, appears to be less
effective as an RNase E inhibitor, only inhibitory small molecules AS2,
AS4 and 5′S1 were taken forwards for further analysis. The chemical
structures of inhibitory small molecules AS2, AS4 and 5′S1 are shown in
Fig. 2B with further information presented in Supplementary Table S1.
3.3. Characterisation of AS2, AS4 and 5′S1 as small molecule inhibitors of
RNase E
To further characterise the inhibitory activity of AS2, AS4 and 5′S1
against RNase E, we developed a novel fluorescence resonance energy
transfer (FRET)-based real-time RNase E assay. We first designed a
partially double-stranded substrate consisting of a 5′ hydroxylated, 3′
FAM-labelled 18-mer “target” RNA and a 5′ monophosphorylated, 3′
TAMRA-labelled 13-mer “guide” RNA, which anneals to the target RNA
with partial complementarity (Fig. 3A). This substrate is based on a
model target-guide substrate [32]. The 5′ hydroxyl of the target RNA
strand prevents direct binding and cleavage of this strand by RNase E
[32]. However, the 5′ monophosphate of the guide RNA facilitates
RNase E-binding and promotes cleavage of the single-stranded A/U-rich
region of the adjacent target RNA strand [32]. In the uncleaved sub-
strate (modified target-guide), the fluorescence of the 3′ FAM group of
the target RNA is quenched by the 3′ TAMRA group of the guide RNA
(Fig. 3A). Endoribonucleolytic cleavage of the 18-mer target RNA by
RNase E NTD results in the release of a 3’ FAM-labelled pentamer and
unquenching of the FAM fluorescence (Fig. 3A). This can be monitored
in real-time as an increase in fluorescence over time.
We decided to use the FRET-based real-time RNase E assay to in-
vestigate the dose-dependent inhibition of RNase E by AS2, AS4 and
5′S1. Each of these three inhibitors had appeared to display dose-de-
pendent inhibition of E. coli RNase E NTD in the discontinuous assay
(see Supplementary Fig. S2B, D and J). To quantify this, the FRET-based
real-time RNase E assay was used to measure the rate of cleavage of
1 μM of the modified target-guide RNA substrate by 5 nM E. coli RNase
E NTD in the presence of 0.25, 0.5, 1, 2, 3, 4, 5 and 10 mM AS2, AS4 or
5′S1. These data were then used to calculate the IC50 for each of the
small molecules, as described in Materials and Methods. IC50 values of
1.9 mM, 2.1 mM and 2.5 mM were calculated for AS2, AS4 and 5′S1,
respectively (Fig. 3B).
Next we used the FRET-based real-time RNase E assay to compare
the kinetics of cleavage of the modified target-guide substrate by E. coli
RNase E NTD. The rate of cleavage of 0.1, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45,
0.5, 0.55, 0.6, 0.8, 1 and 2 μM of the modified target-guide RNA sub-
strate by 5 nM E. coli RNase E NTD in the absence of small molecule
inhibitors and in the presence of 2 mM AS2, AS4 or 5′S1 was measured.
An inhibitor concentration of 2 mM was chosen because this was ap-
proximately equal to the calculated IC50 for all three small molecule
inhibitors (see Fig. 3B). As described in Materials and Methods, these
data were then used to calculate the kinetic parameters, Vmax and Km,
which are presented in Table 1. The presence of any one of the three
small molecule inhibitors both reduced the rate of cleavage of the
modified target-guide RNA substrate by E. coli RNase E NTD (decreased
Vmax) and increased the affinity between E. coli RNase E NTD and the
modified target-guide RNA substrate (decreased Km). This form of
modulation often occurs when an effector/inhibitor binds at a site close
to, but distinct from, the substrate binding pocket and changes the
conformation of the enzyme to favour substrate binding, which also
reduces the enzyme catalytic rate. Therefore, AS2, AS4 and 5′S1 appear
to be allosteric inhibitors of RNase E.
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Fig. 1. Molecular docking of potential small molecule inhibitors into E. coli RNase E NTD. The lowest-energy RNase E-small molecule complex conformations
obtained from the molecular docking of potential small molecule inhibitors AS1-9 into the active site (A) and 5′S1 and 5′S2 into the 5′ sensor region (B) of E. coli
RNase E NTD using 100 starting placement poses. The corresponding docking score is shown above each panel. The docked small molecule is shown as sticks and
labelled in each panel. E. coli RNase E NTD is shown as a ribbon representation (S1 subdomain, blue; DNase I subdomain, red; 5′ sensor subdomain, gold; small
subdomain, grey). Key amino acids, required for catalytic activity and/or substrate binding, are shown as sticks and labelled. (For interpretation of the references to
colour in this figure legend, the reader is referred to the Web version of this article.)
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3.4. Inhibition of F. tularensis and A. baumannii RNase E NTDs by AS2,
AS4 and 5′S1
As small molecule inhibitors of RNase E, AS2, AS4 and 5′S1 are
potential lead molecules for the development of antibacterial agents
targeting RNase E. For an antibiotic to be used effectively, it is useful to
know which bacterial species it is active against. Therefore, we decided
to screen AS2, AS4 and 5′S1 against RNase E NTDs from bacterial
species of importance to the health and/or defence sectors. We selected
the pathogens A. baumannii and F. tularensis because they met this
criteria [21,22], and we have previously characterised the structural
and biochemical properties of their RNase E NTDs [28].
Using the FRET-based real-time RNase E assay, we screened AS2,
AS4 and 5′S1 against F. tularensis and A. baumannii RNase E NTDs. The
rate of cleavage of 1 μMmodified target-guide substrate by 5 nM E. coli,
F. tularensis or A. baumannii RNase E NTD was determined in the ab-
sence of small molecule inhibitors and in the presence of either 2 mM
AS2, AS4 or 5′S1 (Fig. 4). All three small molecules inhibited all three
RNase E NTDs. This was expected given that the key amino acids at the
RNase E active site and the 5′ sensor region, the sites where the small
molecule inhibitors are predicted to bind/block, are absolutely con-
served between E. coli, F. tularensis and A. baumannii [28]. Furthermore,
AS2 and AS4 had a similar effect on the activity of the RNase E NTD
from all three species. However, there was more variability in the re-
lative inhibitory activity of 5′S1 between the RNase E NTDs. Approxi-
mately 60% inhibition was observed with A. baumannii RNase E NTD
while E. coli RNase E NTD was inhibited approximately 40% and F.
tularensis RNase E NTD was only inhibited by around 10%. These dif-
ferences would not have been predicted based on the conservation of
key amino acids at the 5′ sensor region between these three species
[28]. The significant difference with F. tularensis RNase E NTD is in-
teresting given that it has also been reported to exhibit marked
differences in substrate cleavage-site specificity compared to the same
RNase E NTD homologues [28].
4. Discussion
Using a combination of structure-based vHTS and in vitro activity
screening, we have identified three novel small molecule inhibitors of
the potential antibacterial target RNase E: AS2, AS4 and 5′S1 (Figs. 1
and 2). Structure-based vHTS has previously been validated as a sui-
table approach for identifying effective small molecule inhibitors of
RNase E [20]. However, in contrast to the inhibitors identified in the
Kime et al. study [20], the three inhibitors identified here are com-
mercially available and inexpensive (costing less than £2.50 per mg).
This was achieved by starting with a screening library of commercially
available small molecules and then applying a monetary cutoff filter to
the vHTS results. Although we attempted to mask small molecules with
known desirable bioactivity from the monetary cutoff filter, we ac-
knowledge that by using cost as a filter we may have inadvertently
discarded promising inhibitors. Nevertheless, using this approach, we
have successfully identified the first universally accessible small mole-
cule inhibitors of RNase E.
With regard to their inhibitory properties, AS2, AS4 and 5′S1 are
comparable to the small molecule inhibitors reported in Kime et al.
[20]. In each case, the IC50 is in the low millimolar range (Fig. 3) and
there is evidence that they could all have a broad-spectrum effect
(Fig. 4). As potential lead molecules in the development of an anti-
bacterial strategy targeting RNase E, next steps may include exploring
the chemical elaboration of the small molecule inhibitors, in an attempt
to improve their IC50s, and understanding the molecular details of their
mode-of-action. Since all three small molecule inhibitors were derived
from a screening library of chemical building blocks, chemical mod-
ification should be possible in each case. Understanding their mode-of-
Fig. 2. In vitro screening of candidate small molecule inhibitors against E. coli RNase E NTD. (A) Representative 20% denaturing PAGE analysis of the cleavage
of 1 μM 5′-p-RNA13-FAM-3′ by 5 nM E. coli RNase E NTD after incubation at 28 °C for 45 min in the absence of small molecule (-) or in the presence of 10 mM AS1,
AS2, AS3, AS4, AS6, AS7, AS8, AS9, or 5′S1. This is a composite image assembled from multiple gels (complete gels are presented in Supplementary Fig. S2). The
expected position of the bands representing the full-length FAM-labelled 5′-p-RNA13-FAM-3′ RNA substrate and the FAM-labelled pentamer 5′-p-AUUUG-FAM-3′
cleavage product are indicated on the right-hand-side of the gels. (B) The chemical structures of inhibitory small molecules AS2, AS4 and 5′S1 (further details are
presented in Supplementary Table S1).
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action is much more challenging. Although AS2, AS4 and 5′S1 can be
docked into the active site or 5′ sensor region of RNase E, the RNase E-
docked small molecule complex conformations are only predictions and
it is far from certain how, or where, the small molecule inhibitors ac-
tually bind. Critically, our kinetics data suggest allosteric inhibition of
RNase E by all three small molecule inhibitors, implying that they bind
distal to the active site, and the effect of 5′S1 on RNase E NTDs from
different species is variable, despite the absolute conservation of key
amino acids in this region. This raises questions about the assumed
binding sites of the small molecule inhibitors. Elucidating the molecular
Fig. 3. Potency of AS2, AS4 and 5′S1 as small molecule inhibitors of RNase E. (A) Schematic of the FRET-based real-time RNase E assay. The substrate is a
partially double-stranded RNA (modified target-guide) consisting of a 5′ hydroxylated, 3′ FAM-labelled 18-mer “target” RNA and a 5′ monophosphorylated, 3′
TAMRA-labelled 13-mer “guide” RNA, which anneals to the target RNA with partial complementarity. In the uncleaved modified target-guide substrate, the
fluorescence of the 3′ FAM group of the 18-mer target RNA is quenched by the 3′ TAMRA group of the 13-mer guide RNA. Endoribonucleolytic cleavage of the single-
stranded A/U-rich region of the 18-mer target RNA by RNase E NTD, at the position indicated by the arrow, results in the release of a 3′ FAM-labelled pentamer and
the unquenching of the FAM fluorescence. The increase in fluorescence can be monitored in real-time. (B) Plots of the rate of cleavage of 1 μM modified target-guide
RNA substrate by 5 nM E. coli RNase E NTD in the presence of 0.25, 0.5, 1, 2, 3, 4, 5 and 10 mM AS2, AS4 or 5′S1. Data are the average from three experiments and
the error bars represent the standard error of the mean. Data were fitted as described in Materials and Methods to determine the IC50, which is indicated for the
respective small molecule inhibitor in the top right-hand corner of the plot.
Table 1
Kinetic parameters for cleavage of the modified target-guide substrate by
E. coli RNase E NTD. The rate of cleavage of 0.1, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45,
0.5, 0.55, 0.6, 0.8, 1 and 2 μM of the modified target-guide RNA substrate by
5 nM E. coli RNase E NTD in the absence of small molecule inhibitors and in the
presence of 2 mM AS2, AS4 or 5′S1 was measured. Each experiment was per-
formed in triplicate. Data were fitted as described in Materials and Methods to
determine the kinetic parameters, Vmax and Km.
Inhibitor Vmax (pmole/s) Km (nM)
None 0.29 ± 0.01 268 ± 35
AS2 0.12 ± 0.01 64 ± 41
AS4 0.16 ± 0.02 96 ± 48
5′S1 0.15 ± 0.01 100 ± 26
Fig. 4. Inhibition of F. tularensis and A. baumannii RNase E NTDs by AS2, AS4
and 5′S1. The relative rates of cleavage of 1 μM modified target-guide substrate
by 5 nM E. coli (blue), F. tularensis (orange) or A. baumannii (grey) RNase E NTD
in the absence of inhibitor and in the presence of either 2 mM AS2, AS4 or 5′S1.
For each RNase E NTD, the data have been normalised to the cleavage rate
when there was no inhibitor present. Data are the average from duplicate ex-
periments and the error bars represent the standard error of the mean. . (For
interpretation of the references to colour in this figure legend, the reader is
referred to the Web version of this article.)
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details of the binding interactions and mode-of-action for each of the
inhibitors will likely require high-resolution structural studies com-
bined with mutational and molecular dynamics approaches.
Intriguingly, one of the identified small molecule inhibitors of
RNase E, AS4, is GlucN6P, a metabolite that is a precursor of bacterial
cell envelope peptidoglycans and lipopolysaccharides in the hex-
osamine pathway (reviewed in Ref. [33]). The production of GlcN6P
from L-glutamine and fructose-6-phosphate by GlcN6P synthase (GlmS)
is the first step in the synthesis of the bacterial cell envelope and
GlcN6P homeostasis, is tightly controlled through feedback inhibition
loops that modulate translation of GlmS [33]. In Gram-negative bac-
teria, GlmS levels are modulated through a regulatory circuit involving
RNase E-mediated cleavage of glmS-stabilising sRNA GlmZ (reviewed in
Ref. [34]). In the presence of high intracellular concentrations of
GlcN6P, the adaptor protein RapZ specifically interacts with RNase E
and GlmZ, targeting GlmZ for degradation by RNase E [34]. Exactly
how direct inhibition of RNase E by GlcN6P might fit into these me-
chanisms remains to be determined. However, it could serve as a fine-
tuning function in the regulation GlcN6P synthesis. Given that the in-
tracellular concentration of GlucN6P in E. coli is 1.15 mM when glucose
is used as the carbon source [35] and we have determined the IC50 of
AS4/GlucN6P to be 2.1 mM in vitro (Fig. 3), it is theoretically possible
that GlucN6P could regulate RNase E in vivo. Such regulation would
provide support for a communicative link between RNases and cellular
metabolic status that has been proposed previously [36,37].
5. Conclusion
In summary, we have demonstrated inhibition of RNase E NTD by
three novel small molecule inhibitors, AS2, AS4/GlucN6P and 5′S1, in
vitro. These small molecules have potential as lead molecules for the
development of an antibacterial strategy targeting RNase E. In addition,
AS4/GlucN6P, as a natural metabolite, is a potential regulator of RNase
E. To the best of our knowledge, this is the first time that RNase E
activity has been shown to be directly modulated by a small molecule
metabolite.
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